Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent applications relating to the Company's PBGENE-HBV program. The first Notice of Allowance relates to U.S. Patent Application No. 19/347,136, tit.